A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Precision oncology approach for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) is necessary due to its dismal prognosis. We performed a genomic profile-based umbrella trial of patients with platinum-refractory HNSCC (KCSG-TRIUMPH). Here, we present an in-depth report of the the nintedanib arm (arm 3) of the current trial. Materials and Methods The TRIUMPH study was a multicenter, open-label, single-arm phase 2 trial, in which patients were assigned to treatment arms based on next-generation sequencing (NGS)–based, matching genomic profiles. Patients whose tumors harbor fibroblast growth factor receptor (FGFR) alteration were enrolled in the nintedanib arm (arm 3) as part of the TRIUMPH study. The primary endpoint was the overall response rate (ORR), and secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, and biomarker analysis. Results Between October 2017 and August 2020, 207 were enrolled in the TRIUMPH study, and eight were enrolled in the nintedanib arm. ORR and disease control rate were 42.9% and 57.1%, respectively. The median PFS was 5.6 months and the median duration of response was 9.1 months. Median OS was 11.1 months. One patient maintained the partial response for 36 months. Overall, the toxicity profiles were manageable. Conclusion Single-agent nintedanib has demonstrated significant efficacy in FGFR-mutated, recurrent or metastatic HNSCC pati-ents, with tolerable toxicity profiles. The results from the study have provided the basis for routine NGS screening and FGFR-targeted therapy. Because of the small number of patients due to slow accrual in this study, further studies with a larger cohort are warranted for statistical power.
Abstract
Purpose Precision oncology approach for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) is necessary due to its dismal prognosis. We performed a genomic profile-based umbrella trial of patients with platinum-refractory HNSCC (KCSG-TRIUMPH). Here, we present an in-depth report of the the nintedanib arm (arm 3) of the current trial. Materials and Methods The TRIUMPH study was a multicenter, open-label, single-arm phase 2 trial, in which patients were assigned to treatment arms based on next-generation sequencing (NGS)–based, matching genomic profiles. Patients whose tumors harbor fibroblast growth factor receptor (FGFR) alteration were enrolled in the nintedanib arm (arm 3) as part of the TRIUMPH study. The primary endpoint was the overall response rate (ORR), and secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, and biomarker analysis. Results Between October 2017 and August 2020, 207 were enrolled in the TRIUMPH study, and eight were enrolled in the nintedanib arm. ORR and disease control rate were 42.9% and 57.1%, respectively. The median PFS was 5.6 months and the median duration of response was 9.1 months. Median OS was 11.1 months. One patient maintained the partial response for 36 months. Overall, the toxicity profiles were manageable. Conclusion Single-agent nintedanib has demonstrated significant efficacy in FGFR-mutated, recurrent or metastatic HNSCC pati-ents, with tolerable toxicity profiles. The results from the study have provided the basis for routine NGS screening and FGFR-targeted therapy. Because of the small number of patients due to slow accrual in this study, further studies with a larger cohort are warranted for statistical power.
참고문헌 (32)
- Mody MD, "Head and neck cancer", Lancet, 398, pp.2289~2299 (2021)
- Vermorken JB, "Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and", or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy, 2007, pp.25, 2171~2177
- Morris LG, "The molecular landscape of recurrent and metastatic head and neck cancers : insights from a precision oncology sequencing platform", JAMA Oncol, 3, pp.244~255 (2017)
- Marret G, "Genomic alterations in head and neck squamous cell carcinoma : level of evidence according to ESMO Scale for Clinical Actionability of Molecular Targets(ESCAT)", JCO Pre cis Oncol, 5, pp.215~226 (2021)
- Keam B, "Personalized biomarker-based umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma : KCSG HN 15-16 TRIUMPH trial", J Clin Oncol (2023)[DOI]
- Cancer Genome Atlas Network, "Comprehensive genomic characterization of head and neck squamous cell carcinomas", Nature, 517, pp.576~582 (2015)
- Wang Z, "Therapeutic targeting of FGFR signal ing in head and neck cancer", Cancer J, 28, pp.354~362 (2022)
- Seiwert TY, "Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas", Clin Cancer Res, 21, pp.632~641 (2015)
- Roth GJ, "Nintedanib : from discovery to the clinic", J Med Chem, 58, pp.1053~1063 (2015)
- Hilberg F, "BIBF 1120 : triple angiokinase inhi bitor with sustained receptor blockade and good antitumor efficacy", Cancer Res, 68, pp.4774~4782 (2008)
- Reck M, "Docetaxel plus nintedanib versus doc etaxel plus placebo in patients with previously treated non small-cell lung cancer(LUME-Lung 1) : a phase 3, double-blind, randomised controlled trial", Lancet Oncol, 15, pp.143~155 (2014)
- Richeldi L, "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2071~2082 (2014)
- Hanna NH, "Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer(LUME-Lung 2) : a randomized, double-blind, phase III trial", Lung Cancer, 102, pp.65~73 (2016)
- McCormack PL, "Nintedanib : first global approval", Drugs, 75, pp.129~139 (2015)
- Lim SM, "Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squa mous cell carcinoma", Cancer Res Treat, 51, pp.300~312 (2019)
- "Sickle: a sliding-window, adaptive, quality based trimming tool for FastQ files (version 1.33)" (2011)[URL]
- Li H, "Fast and accurate short read alignment with Burrows-Wheeler transform", Bioinformatics, 25, pp.1754~1760 (2009)
- McKenna A, "The Genome Analysis Toolkit : a MapRe duce framework for analyzing next-generation DNA sequenc ing data", Genome Res, 20, pp.1297~1303 (2010)
- Otsubo K, "Nintedanib plus chemotherapy for nons mall cell lung cancer with idiopathic pulmonary fibrosis : a randomised phase 3 trial", Eur Respir J, 60, pp.2200380~ (2022)
- Ou J, "trackViewer : a Bioconductor package for inter active and integrative visualization of multi-omics data", Nat Methods, 16, pp.453~454 (2019)
- Conley BA, "The exceptional responders initiative : feasibil ity of a National Cancer Institute pilot study", J Natl Cancer Inst, 113, pp.27~37 (2021)
- Helsten T, "The FGFR landscape in cancer : analysis of 4, 853 tumors by next-generation sequencing", Clin Cancer Res, 22, pp.259~267 (2016)
- Hussain SA, "Addition of nintedanib or placebo to neoad juvant gemcitabine and cisplatin in locally advanced mus cle-invasive bladder cancer(NEOBLADE) : a double-blind, randomised, phase 2 trial", Lancet Oncol, 23, pp.650~658 (2022)
- Barra F, "Nintedanib for advanced epithelial ovarian cancer: a change of perspec tive? Summary of evidence from a systematic review", Gynecol Obstet Invest, 84, pp.107~117 (2019)
- Ray-Coquard I, "Final results from GCIG", ENGOT, Int J Cancer, pp.2020, 146[DOI]
- Kim Y, "Clini cal trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck : a multicenter phase 2 study(Korean Cancer Study Group HN14-01)", Can cer, 123, pp.1958~1964 (2017)
- Pearson A, "High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial", Cancer Discov, 6, pp.838~851 (2016)
- Loriot Y, "Erdafitinib in locally advanced or metastatic urothelial carcinoma", N Engl J Med, 381, pp.338~348 (2019)
- Abou-Alfa GK, "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma : a multicentre, open-label, phase 2 study", Lancet Oncol, 21, pp.671~684 (2020)
- Javle M, "Infigratinib(BGJ398)in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements : mature results from a multicentre, open-label, single-arm, phase 2 study", Lancet Gastroenterol Hepatol, 6, pp.803~815 (2021)
- Goyal L, "Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma", N Engl J Med, 388, pp.22839~ (2023)
- Ellinghaus P, "Patient selection approaches in FGFR inhibitor trials : many paths to the same end?", Cells, 11, pp.3180~ (2022)